U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

PubAg

Main content area

You searched for: Journal Vaccine Remove constraint Journal: Vaccine
Start Over

Search

12,187  Search Results

« Previous | 1 - 50 of 12,187 |
Number of results to display per page

Search Results

1. #DoctorsSpeakUp: Lessons learned from a pro-vaccine Twitter event

Author:
Beth L. Hoffman; Jason B. Colditz; Ariel Shensa; Riley Wolynn; Sanya Bathla Taneja; Elizabeth M. Felter; Todd Wolynn; Jaime E. Sidani
Source:
Vaccine 2021 v.39 no.19 pp. 2684-2691
ISSN:
0264-410X
Subject:
activists; advocacy; automation; data collection; vaccines
Abstract:
... In response to growing anti-vaccine activism on social media, the #DoctorsSpeakUp event was designed to promote pro-vaccine advocacy. This study aimed to analyze Twitter content related to the event to determine (1) characteristics of the Twitter users who authored these tweets, (2) the proportion of tweets expressing pro-vaccine compared to anti-vaccine sentiment, and (3) the content of these twe ...
DOI:
10.1016/j.vaccine.2021.03.061

2. (S)pin the flu vaccine: Recipes for concern

Author:
Jeanine P.D. Guidry; Ioana A. Coman; Emily K. Vraga; Nicole H. O'Donnell; Nihar Sreepada
Source:
Vaccine 2020 v.38 no.34 pp. 5498-5506
ISSN:
0264-410X
Subject:
World Health Organization; health beliefs; influenza; influenza vaccines; misinformation; vaccination; viruses
Abstract:
... Influenza epidemics happen yearly, and the World Health Organization estimates that the virus is connected to between 290,000 and 650,000 annual deaths. The most effective way to prevent seasonal influenza is vaccination. The prevalence of vaccine misinformation on social media is increasing, but the visual platform Pinterest is understudied in this area. The current study is the first to explore ...
DOI:
10.1016/j.vaccine.2020.06.012

3. 1,5-Iodonaphthyl azide-inactivated V3526 protects against aerosol challenge with virulent venezuelan equine encephalitis virus

Author:
Paridhi Gupta; Anuj Sharma; Kevin B. Spurgers; Russell R. Bakken; Lori T. Eccleston; Jeffrey W. Cohen; Shelley P. Honnold; Pamela J. Glass; Radha K. Maheshwari
Source:
Vaccine 2016 v.34 no.25 pp. 2762-2765
ISSN:
0264-410X
Subject:
Venezuelan equine encephalitis virus; aerosols; disease control; immunization; vaccines; virulence
Abstract:
... Venezuelan equine encephalitis virus (VEEV) is a New World alphavirus. VEEV is highly infectious in aerosolized form and has been identified as a bio-terrorism agent. There is no licensed vaccine for prophylaxis against VEEV. The current IND vaccine is poorly immunogenic and does not protect against an aerosol challenge with virulent VEEV. We have previously shown that VEEV inactivated by 1,5-iodo ...
DOI:
10.1016/j.vaccine.2016.04.049

4. 10-valent pneumococcal conjugate vaccine (PCV10) decreases metabolic activity but not nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae

Author:
Dafne C. Andrade; Igor C. Borges; Maiara L. Bouzas; Juliana R. Oliveira; Kiyoshi F. Fukutani; Artur T. Queiroz; Camila Indiani de Oliveira; Aldina Barral; Johan Van Weyenbergh; Cristiana Nascimento-Carvalho
Source:
Vaccine 2017 v.35 no.33 pp. 4105-4111
ISSN:
0264-410X
Subject:
Haemophilus influenzae; Moraxella catarrhalis; Staphylococcus aureus; Streptococcus pneumoniae; biochemical pathways; children; cross-sectional studies; messenger RNA; metabolism; metagenomics; pathogens; patients; respiratory tract diseases; ribosomal DNA; ribosomal RNA; transcriptomics; vaccination; vaccines
Abstract:
... The effect of pneumococcal vaccination is widely variable when measured by nasopharyngeal carriage of vaccine and non-vaccine targets. The aim of this study was to compare the carriage rates and metabolic activity of Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae and Moraxella catarrhalis among children who were or were not vaccinated with PCV10.We included children with a ...
DOI:
10.1016/j.vaccine.2017.06.048

5. 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): A phase 3, open-label trial

Author:
Sven Arne Silfverdal; Carl-Erik Flodmark; Lars Rombo; Susan P. Tansey; Mohinder Sidhu; James Trammel; Emilio A. Emini; William C. Gruber; Daniel A. Scott; Alejandra Gurtman; On behalf of the 3012 study group
Source:
Vaccine 2013 v.31 no.9 pp. 1284-1292
ISSN:
0264-410X
Subject:
children; fever; immune response; immunoglobulin G; infancy; infants; serotypes; toddlers; vaccination; vaccines
Abstract:
... As 13-valent pneumococcal conjugate vaccine (PCV13) is introduced, children who began vaccination with 7-valent pneumococcal conjugate vaccine (PCV7) may complete their vaccination with PCV13. This open-label phase 3 study evaluated immunogenicity and safety of PCV13 in Swedish infants and toddlers previously given 1 or 2 doses of PCV7 during infancy.Healthy infants previously given PCV7 at ages 3 ...
DOI:
10.1016/j.vaccine.2012.12.066

6. 13-Valent vaccine serotype pneumococcal community acquired pneumonia in adults in high clinical risk groups

Author:
Priya Daniel; Chamira Rodrigo; Thomas Bewick; Carmen Sheppard; Sonia Greenwood; Tricia M. McKeever; Caroline Trotter; Wei Shen Lim
Source:
Vaccine 2018 v.36 no.12 pp. 1614-1620
ISSN:
0264-410X
Subject:
etiology; antigen detection; blood serum; immunoassays; at-risk population; serotypes; vaccines; pneumonia; risk factors; kidney diseases; latex; patients; agglutination; adults; United Kingdom
Abstract:
... There is debate regarding the value of vaccinating adults with the 13-valent pneumococcal conjugate vaccine (PCV-13). This analysis was conducted to investigate the risk of PCV-13 serotype community acquired pneumonia (CAP) in hospitalised adults with co-morbid disease and risk factors for pneumococcal disease in the UK.Consecutive adults hospitalised (2008–2013) with a primary diagnosis of CAP, w ...
DOI:
10.1016/j.vaccine.2018.02.005

7. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A

Author:
David Cooper; Xinhong Yu; Mohinder Sidhu; Moon H. Nahm; Philip Fernsten; Kathrin U. Jansen
Source:
Vaccine 2011 v.29 no.41 pp. 7207-7211
ISSN:
0264-410X
Subject:
Streptococcus pneumoniae; antiserum; epitopes; humans; immunization; infants; serotypes; vaccines
Abstract:
... The introduction of a 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 dramatically reduced the incidence of invasive pneumococcal disease (IPD) caused by the seven serotypes covered by the vaccine. Following the introduction of PCV7, which contains a serotype 6B conjugate, some decrease in IPD due to serotype 6A was noted suggesting that the serotype 6B conjugate provided some partial cross ...
DOI:
10.1016/j.vaccine.2011.06.056
PubMed:
21689707
PubMed Central:
PMC3170457

8. A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation

Author:
Robert Cohen; Emmanuelle Varon; Catherine Doit; Catherine Schlemmer; Olivier Romain; Franck Thollot; Stéphane Béchet; Stéphane Bonacorsi; Corinne Levy
Source:
Vaccine 2015 v.33 no.39 pp. 5118-5126
ISSN:
0264-410X
Subject:
Streptococcus pneumoniae; children; clinical examination; demographic statistics; medical history; monitoring; otitis media; patients; pediatricians; penicillins; serotypes; surveys; vaccines
Abstract:
... This nasopharyngeal (NP) carriage surveillance study was requested by the European Agency for the Evaluation of Medicinal Products as a post-licensing commitment to determine whether the use of the pneumococcal conjugate vaccines (PCVs) including 7 then 13 valents (introduced in 2001 and 2010, respectively) caused a shift in the distribution of Streptococcus pneumoniae serotypes in children with a ...
DOI:
10.1016/j.vaccine.2015.08.010

9. IL- 15 aggravates atherosclerotic lesion development in LDL receptor deficient mice

Author:
Thomas van Es; Gijs H.M. van Puijvelde; Ingrid N. Michon; Eva J.A. van Wanrooij; Paula de Vos; Niels Peterse; Theo J.C. van Berkel; Johan Kuiper
Source:
Vaccine 2011 v.29 no.5 pp. 976-983
ISSN:
0264-410X
Subject:
DNA; atherosclerosis; cytotoxicity; diet; hypercholesterolemia; interleukin-15; leukocytes; low density lipoprotein; macrophages; mice; neutralization; spleen; splenocytes; tumor necrosis factor-alpha; vaccination; vaccines
Abstract:
... BACKGROUND: Interleukin 15 (IL-15) is a pro-inflammatory cytokine involved in inflammatory diseases and IL-15 is expressed in atherosclerotic plaques. METHODS: To establish the role of IL-15 in atherosclerosis we studied the effect of IL-15 on atherosclerosis associated cells in vitro and in vivo by neutralizing IL-15 using a DNA vaccination strategy. RESULTS: Upon feeding a Western type diet LDLr ...
DOI:
10.1016/j.vaccine.2010.11.037

10. A 16-year review of seroprevalence studies on measles and rubella

Author:
Wayne Dimech; Mick N. Mulders
Source:
Vaccine 2016 v.34 no.35 pp. 4110-4118
ISSN:
0264-410X
Subject:
National Library of Medicine; World Health Organization; adolescents; children; developing countries; enzyme immunoassays; females; guidelines; immigration; infants; males; maternal immunity; monitoring; risk; seroprevalence; vaccination; vaccines; young adults
Abstract:
... The determination of the seroprevalence of vaccine-preventable diseases is critical in monitoring the efficacy of vaccination programmes and to assess the gaps in population immunity but requires extensive organisation and is time and resource intensive. The results of the studies are frequently reported in peer-reviewed scientific, government and non-government publications. A review of scientifi ...
DOI:
10.1016/j.vaccine.2016.06.002

11. IL- 17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine

Author:
Ivana B. Campos; Muriel Herd; Kristin L. Moffitt; Ying-Jie Lu; Michelle Darrieux; Richard Malley; Luciana C.C. Leite; Viviane M. Gonçalves
Source:
Vaccine 2017 v.35 no.9 pp. 1306-1315
ISSN:
0264-410X
Subject:
antibodies; bacteria; complement; encapsulation; flow cytometry; humans; immunization; interleukin-17; mice; models; phagocytes; phagocytosis; serotypes; vaccines
Abstract:
... The pneumococcal whole cell vaccine (PWCV) has been investigated as an alternative to polysaccharide-based vaccines currently in use. It is a non-encapsulated killed vaccine preparation that induces non-capsular antibodies protecting mice against invasive pneumococcal disease (IPD) and reducing nasopharyngeal (NP) carriage via IL-17A activation of mouse phagocytes. Here, we show that PWCV induces ...
DOI:
10.1016/j.vaccine.2017.01.030

12. 17β-Estradiol restores antibody responses to an influenza vaccine in a postmenopausal mouse model

Author:
Doan C. Nguyen; Feda Masseoud; Xiuhua Lu; Franco Scinicariello; Suryaprakash Sambhara; Roberta Attanasio
Source:
Vaccine 2011 v.29 no.14 pp. 2515-2518
ISSN:
0264-410X
Subject:
Orthomyxoviridae; animal models; blood serum; estradiol; hormone replacement therapy; immune response; influenza; mice; neutralizing antibodies; ovariectomy; postmenopause; vaccination; vaccines; women
Abstract:
... Post-menopausal women belong to an age group that is highly susceptible to influenza infection and its most serious complications. However, data on the immunogenicity of influenza vaccines in these women is limited. Therefore, the antibody response to influenza vaccination was assessed in a postmenopausal mouse model. An inactivated-detergent-split vaccine from the A/New Caledonia/20/99 (H1N1) inf ...
DOI:
10.1016/j.vaccine.2011.01.080

13. The 1918 influenza pandemic hastened the decline of tuberculosis in the United States: An age, period, cohort analysis

Author:
Andrew Noymer
Source:
Vaccine 2011 v.29S2 no. pp. B38
ISSN:
0264-410X
Subject:
demographic statistics; influenza; mortality; pandemic; people; tuberculosis; vaccines; United States
Abstract:
... The effect of the 1918 influenza pandemic on other diseases is a neglected topic in historical epidemiology. This paper takes up the hypothesis that the influenza pandemic affected the long-term decline of tuberculosis through selective mortality, such that many people with tuberculosis were killed in 1918, depressing subsequent tuberculosis mortality and transmission. Regularly collected vital st ...
DOI:
10.1016/j.vaccine.2011.02.053
PubMed:
21757102
PubMed Central:
PMC3139993

14. The 1918 influenza pandemic in Florianopolis: A subtropical city in Brazil

Author:
Wladimir J. Alonso; Francielle C. Nascimento; Rodolfo Acuña-Soto; Cynthia Schuck-Paim; Mark A. Miller
Source:
Vaccine 2011 v.29S2 no. pp. B16
ISSN:
0264-410X
Subject:
bronchitis; death; influenza; mortality; pandemic; pneumonia; spring; summer; vaccines; young adults; Brazil
Abstract:
... Few studies have addressed the impact and dynamics of the 1918–1919 influenza pandemic in tropical and sub-tropical areas. To help cover this gap, we analyzed all death certificates issued from October 1913 to June 1921 in Florianopolis (Brazil), a subtropical state capital with a population of 41,298 inhabitants in 1920. In November and December 1918 (spring) there were a total of 70 and 14 death ...
DOI:
10.1016/j.vaccine.2011.02.047

15. The 1918–1920 influenza pandemic in Peru

Author:
G. Chowell; C. Viboud; L. Simonsen; M.A. Miller; J. Hurtado; G. Soto; R. Vargas; M.A. Guzman; M. Ulloa; C.V. Munayco
Source:
Vaccine 2011 v.29S2 no. pp. B21
ISSN:
0264-410X
Subject:
cities; coasts; influenza; models; mortality; pandemic; quantitative analysis; respiratory rate; vaccines; viruses; Africa; Amazonia; Asia; Latin America; Peru
Abstract:
... BACKGROUND: Increasing our knowledge of past influenza pandemic patterns in different regions of the world is crucial to guide preparedness plans against future influenza pandemics. Here, we undertook extensive archival collection efforts from three representative cities of Peru—Lima in the central coast, Iquitos in the northeastern Amazon region, Ica in the southern coast—to characterize the temp ...
DOI:
10.1016/j.vaccine.2011.02.048
PubMed:
21757099
PubMed Central:
PMC3144394

16. The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets

Author:
Zhongying Chen; Lomi Kim; Kanta Subbarao; Hong Jin
Source:
Vaccine 2012 v.30 no.15 pp. 2516-2522
ISSN:
0264-410X
Subject:
Influenza A virus; amino acids; antibodies; birds; cross reaction; ferrets; humans; influenza; pandemic; proteins; sialidase; vaccines; viruses
Abstract:
... A miniaturized neuraminidase inhibition (NI) assay using HA-mismatched H6 reassortant viruses was performed to examine the neuraminidase (NA)-specific antibody response in ferrets immunized with live-attenuated influenza vaccine (LAIV) strains. The strains tested possessed different NAs derived from seasonal H1N1 and H3N2, 2009 pandemic H1N1, and the highly pathogenic influenza H5N1 virus. The ant ...
DOI:
10.1016/j.vaccine.2012.01.090
PubMed:
22330124
PubMed Central:
PMC4792253

17. 2009–2010 seasonal and pandemic A (H1N1) influenza vaccination among healthcare workers

Author:
Maria Teresa del Campo; Villamor José Miguel; Cáceres Susana; Gómez Ana; Ledesma Gregoria; Mahíllo-Fernández Ignacio
Source:
Vaccine 2011 v.29 no.20 pp. 3703-3707
ISSN:
0264-410X
Subject:
compliance; health care workers; influenza; pandemic; patients; vaccination; vaccines
Abstract:
... Influenza vaccination recommendations are traditionally met with low compliance by healthcare workers (HCWs). The aim of this study is to analyze influenza vaccination among HCWs following a vaccination strategy characterized by an increased effort to maximize the hospital vaccination rate. For this, 2009–2010 seasonal and pandemic influenza vaccination rates among 2739 HCWs at a tertiary universi ...
DOI:
10.1016/j.vaccine.2011.03.021

18. The 2015 global production capacity of seasonal and pandemic influenza vaccine

Author:
Kenneth A. McLean; Shoshanna​ Goldin; Claudia Nannei; Erin Sparrow; Guido Torelli
Source:
Vaccine 2016 v.34 no.45 pp. 5410-5413
ISSN:
0264-410X
Subject:
adjuvants; developing countries; influenza; influenza vaccines; infrastructure; pandemic; surveys; South East Asia
Abstract:
... A global shortage and inequitable access to influenza vaccines has been cause for concern for developing countries who face dire consequences in the event of a pandemic. The Global Action Plan for Influenza Vaccines (GAP) was launched in 2006 to increase global capacity for influenza vaccine production to address these concerns. It is widely recognized that well-developed infrastructure to produce ...
DOI:
10.1016/j.vaccine.2016.08.019
PubMed:
27531411
PubMed Central:
PMC5357707

19. The 2015–2016 influenza epidemic in Beijing, China: Unlike elsewhere, circulation of influenza A(H3N2) with moderate vaccine effectiveness

Author:
Li Zhang; Yang Pan; Volker Hackert; Wim van der Hoek; Adam Meijer; Thomas Krafft; Peng Yang; Quanyi Wang
Source:
Vaccine 2018 v.36 no.33 pp. 4993-5001
ISSN:
0264-410X
Subject:
Influenza A virus; experimental design; inactivated vaccines; influenza; patients; vaccination; viruses; China
Abstract:
... While the 2015–2016 influenza season in the northern hemisphere was dominated by A(H1N1)pdm09 and B/Victoria viruses, in Beijing, China, there was also significant circulation of influenza A(H3N2) virus. In this report we estimate vaccine effectiveness (VE) against influenza A(H3N2) and other circulating viruses, and describe further characteristics of the 2015–2016 influenza season in Beijing.We ...
DOI:
10.1016/j.vaccine.2018.07.017

20. 2016–2017 Arkansas mumps outbreak in a close-knit community: Assessment of the economic impact and response strategies

Author:
Jamison Pike; Mona Marin; Angela Guo; Dirk Haselow; Haytham Safi; Fangjun Zhou
Source:
Vaccine 2020 v.38 no.6 pp. 1481-1485
ISSN:
0264-410X
Subject:
adults; economic impact; education; extended families; outreach; politics; public health; vaccination; vaccines; Arkansas
Abstract:
... On August 8, 2016, a confirmed case of mumps was reported to the Arkansas Department of Health (ADH) in an adult resident of Springdale, Arkansas. By July 2017, nearly 3,000 cases of mumps were reported to ADH from 37 of the 75 counties in Arkansas. Over 50% of cases were in the Arkansas Marshallese community, a close-knit community characterized by large, and extended families sharing the same li ...
DOI:
10.1016/j.vaccine.2019.11.066

21. IL- 22 deficiency increases CD4 T cell responses to mucosal immunization

Author:
Scott A. Budda; Lauren A. Zenewicz
Source:
Vaccine 2018 v.36 no.25 pp. 3694-3700
ISSN:
0264-410X
Subject:
CD4-positive T-lymphocytes; alum; animal tissues; antigens; antimicrobial peptides; apoptosis; cell proliferation; cholera toxin; cytokines; epithelial cells; immune response; infectious diseases; mice; mucins; pathogens; vaccination; vaccines
Abstract:
... Mucosal vaccines are a promising platform for combatting infectious diseases for which we still lack effective preventative measures. Optimizing these vaccines to generate the best protective immune responses with the least complicated immunization regimen is imperative. Mucosal barriers are the first line of defense against many pathogens and, as such, we looked to their biology for strategies to ...
DOI:
10.1016/j.vaccine.2018.05.011

22. 23-valent pneumococcal polysaccharide vaccine improves survival in dialysis patients by preventing cardiac events

Author:
Hiroaki Ihara; Kan Kikuchi; Hiromi Taniguchi; Shogo Fujita; Yuki Tsuruta; Motoyasu Kato; Yoichiro Mitsuishi; Ken Tajima; Yuzo Kodama; Fumiyuki Takahashi; Kazuhisa Takahashi; Nakanobu Azuma
Source:
Vaccine 2019 v.37 no.43 pp. 6447-6453
ISSN:
0264-410X
Subject:
Streptococcus pneumoniae; confidence interval; death; dialysis; medical records; mortality; patients; pneumonia; polysaccharides; prognosis; risk; risk reduction; vaccination; vaccines
Abstract:
... Immunodeficient patients are recommended to receive pneumococcal vaccination. However, there is limited evidence showing effectiveness of the polysaccharide vaccine. Polysaccharide vaccination has shown an association with cardiovascular event risk reduction. We assessed the efficacy of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in relation to the risk of hospitalization and death ...
DOI:
10.1016/j.vaccine.2019.08.088

23. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old—Taiwan's PPV vaccination program

Author:
Ying-Huang Tsai; Meng-Jer Hsieh; Chee-Jen Chang; Yu-Wen Wen; Han-Chung Hu; Yen-Nan Chao; Yhu-Chering Huang; Cheng-Ta Yang; Chung-Chi Huang
Source:
Vaccine 2015 v.33 no.25 pp. 2897-2902
ISSN:
0264-410X
Subject:
Streptococcus pneumoniae; chronic diseases; databases; death; disease severity; elderly; gender; health insurance; health services; influenza; morbidity; mortality; odds ratio; people; pneumonia; polysaccharides; regression analysis; vaccination; vaccines; Taiwan
Abstract:
... Pneumococcal infection is a serious cause of mortality and morbidity in the elderly. A nationwide pneumococcal polysaccharide vaccine (PPV) program for elderly adults aged 75 years and older was conducted in Taiwan in 2008. The efficacy of the PPV in this very elderly population was evaluated.The data were analyzed using the Taiwan National Health Insurance Research Database (NHIRD), the cause-of- ...
DOI:
10.1016/j.vaccine.2015.04.068

24. IL- 33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine

Author:
Sanghita Sarkar; Michael S. Piepenbrink; Madhubanti Basu; Juilee Thakar; Michael C. Keefer; Ann J. Hessell; Nancy L. Haigwood; James J. Kobie
Source:
Vaccine 2019 v.37 no.17 pp. 2322-2330
ISSN:
0264-410X
Subject:
B-lymphocytes; Human immunodeficiency virus 1; Macaca mulatta; adjuvants; alum; antibodies; blood serum; humoral immunity; immunogenicity; immunoglobulin G; immunoglobulin M; mice; neutralization; plasmids; vaccination; vaccines
Abstract:
... Induction of a sustained and broad antibody (Ab) response is a major goal in developing a protective HIV-1 vaccine. DNA priming alone shows reduced levels of immunogenicity; however, when combined with protein boosting is an attractive vaccination strategy for induction of humoral responses. Using the VC10014 DNA and protein-based vaccine consisting of HIV-1 envelope (Env) gp160 plasmids and trime ...
DOI:
10.1016/j.vaccine.2019.03.044
PubMed:
30926296
PubMed Central:
PMC6506229

25. IL- 4 and IL-13 mediated down-regulation of CD8 expression levels can dampen anti-viral CD8+ T cell avidity following HIV-1 recombinant pox viral vaccination

Author:
Danushka K. Wijesundara; Ronald J. Jackson; David C. Tscharke; Charani Ranasinghe
Source:
Vaccine 2013 v.31 no.41 pp. 4548-4555
ISSN:
0264-410X
Subject:
CD8-positive T-lymphocytes; Human immunodeficiency virus 1; antibodies; interferon-gamma; interleukin-13; interleukin-2; interleukin-4; mice; neoplasms; signal transduction; transcription factors; tumor necrosis factors; vaccination; vaccines
Abstract:
... We have shown that mucosal HIV-1 recombinant pox viral vaccination can induce high, avidity HIV-specific CD8+ T cells with reduced interleukin (IL)-4 and IL-13 expression compared to, systemic vaccine delivery. In the current study how these cytokines act to regulate anti-viral CD8+ T, cell avidity following HIV-1 recombinant pox viral prime-boost vaccination was investigated. Out of a panel of T ...
DOI:
10.1016/j.vaccine.2013.07.062

26. 5 ways statistics can fool you—Tips for practicing clinicians

Author:
Colin P. West; Denise M. Dupras
Source:
Vaccine 2013 v.31 no.12 pp. 1550-1552
ISSN:
0264-410X
Subject:
confidence interval; patients; risk; vaccines
Abstract:
... Published literature suggests that many clinicians are not fully equipped to evaluate and apply research reports for the care of their patients. In this article, we introduce and illustrate five basic statistical concepts that can significantly impact the interpretation of the medical literature and its application to the care of patients, drawing examples from the vaccine literature: (i) consider ...
DOI:
10.1016/j.vaccine.2012.11.086

27. A 5-year Chlamydia vaccination programme could reverse disease-related koala population decline: Predictions from a mathematical model using field data

Author:
Andrew P. Craig; Jon Hanger; Jo Loader; William A.H. Ellis; John Callaghan; Cathryn Dexter; Darryl Jones; Kenneth W. Beagley; Peter Timms; David P. Wilson
Source:
Vaccine 2014 v.32 no.33 pp. 4163-4170
ISSN:
0264-410X
Subject:
Chlamydia; Phascolarctos cinereus adustus; females; half life; morbidity; mortality; population growth; prediction; simulation models; uncertainty; vaccination; vaccines; Queensland
Abstract:
... Many koala populations around Australia are in serious decline, with a substantial component of this decline in some Southeast Queensland populations attributed to the impact of Chlamydia. A Chlamydia vaccine for koalas is in development and has shown promise in early trials. This study contributes to implementation preparedness by simulating vaccination strategies designed to reverse population d ...
DOI:
10.1016/j.vaccine.2014.05.049

28. The 5As: A practical taxonomy for the determinants of vaccine uptake

Author:
Angus Thomson; Karis Robinson; Gaëlle Vallée-Tourangeau
Source:
Vaccine 2016 v.34 no.8 pp. 1018-1024
ISSN:
0264-410X
Subject:
adults; affordability; childhood; people; taxonomy; vaccination; vaccines
Abstract:
... Suboptimal vaccine uptake in both childhood and adult immunisation programs limits their full potential impact on global health. A recent progress review of the Global Vaccine Action Plan stated that “countries should urgently identify barriers and bottlenecks and implement targeted approaches to increase and sustain coverage”. However, vaccination coverage may be determined by a complex mix of de ...
DOI:
10.1016/j.vaccine.2015.11.065

29. IL- 6 production following vaccination in pigs—An additional immune response parameter for assessing FMD vaccine efficacy?

Author:
Sarah J. Cox; Simon Gubbins; Paul V. Barnett
Source:
Vaccine 2011 v.29 no.29-30 pp. 4704-4708
ISSN:
0264-410X
Subject:
animal welfare; blood serum; foot-and-mouth disease; immune response; interleukin-6; statistical analysis; swine; vaccination; vaccines; viruses
Abstract:
... Foot-and-mouth disease vaccine potency testing involving live virus challenge can be problematical in pigs. Alternative methods of assessing vaccine efficacy are therefore desirable. Here we investigate the link between IL-6 in blood at time of challenge and protection against challenge by carrying out statistical analyses utilising data from six separate potency tests performed in swine with the ...
DOI:
10.1016/j.vaccine.2011.04.100

30. 7-Valent pneumococcal conjugate vaccine and otitis media: Effectiveness of a 2-dose versus 3-dose primary series

Author:
Charles Stoecker; Lee M. Hampton; Matthew R. Moore
Source:
Vaccine 2012 v.30 no.44 pp. 6256-6262
ISSN:
0264-410X
Subject:
children; cost effectiveness; databases; insurance; otitis media; vaccination; vaccines; United States
Abstract:
... BACKGROUND: Seven-valent pneumococcal conjugate vaccination (PCV7) has been shown to reduce rates of otitis media (OM) when given as a 2- or 3-dose primary series followed by a booster dose. However, data on the 2- or 3-dose primary series’ relative effectiveness against OM is very limited. Using data from the United States after the 2000 introduction of PCV7, we compared the effectiveness of a 2- ...
DOI:
10.1016/j.vaccine.2012.08.011

31. An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines

Author:
Fei Liu; Canbin Feng; Shiqi Xu; Qiang Wu; Jian Tang; Yan Chen; Ruisheng Xu; Fuliang Chen; Ni Gao; Zhengzheng Xu; Shihui Gu; Yang Lan; Haibo Zhou; Xinde Hu; Xiaojing Wang
Source:
Vaccine 2022 v.40 no.9 pp. 1208-1212
ISSN:
0264-410X
Subject:
COVID-19 infection; Pseudovirus; Severe acute respiratory syndrome coronavirus 2; pandemic; vaccination; vaccines
Abstract:
... The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in catastrophic damage worldwide. Accordingly, the development of powerful, safe, easily accessible vaccines with long-term effectiveness is understood as an urgently needed countermeasure against this ongoing pandemic. Guided by this strong promise of using AAVs, we ...
DOI:
10.1016/j.vaccine.2022.01.030

32. ADE and dengue vaccination

Author:
Ruth Aralí Martínez-Vega; Gabriel Carrasquila; Expedito Luna; José Ramos-Castañeda
Source:
Vaccine 2017 v.35 no.32 pp. 3910-3912
ISSN:
0264-410X
Subject:
Dengue virus; dengue; models; vaccination; vaccines
Abstract:
... The vaccine against Dengue virus (DENV), Dengvaxia® (CYD), produced by Sanofi-Pasteur, has been registered by several national regulatory agencies; nevertheless, the performance and security of this vaccine have been challenged in a series of recent papers. In this work, we intend to contribute to the debate by analyzing the concept of an enhancing vaccine, presenting objections to the epidemiolog ...
DOI:
10.1016/j.vaccine.2017.06.004

33. The ADVANCE Code of Conduct for collaborative vaccine studies

Author:
Xavier Kurz; Vincent Bauchau; Patrick Mahy; Steffen Glismann; Lieke Maria van der Aa; François Simondon; for the ADVANCE consortium
Source:
Vaccine 2017 v.35 no.15 pp. 1844-1855
ISSN:
0264-410X
Subject:
funding; governance; green infrastructure; influenza; monitoring; pandemic; public health; vaccine development; vaccines; Europe
Abstract:
... Lessons learnt from the 2009 (H1N1) flu pandemic highlighted factors limiting the capacity to collect European data on vaccine exposure, safety and effectiveness, including lack of rapid access to available data sources or expertise, difficulties to establish efficient interactions between multiple parties, lack of confidence between private and public sectors, concerns about possible or actual co ...
DOI:
10.1016/j.vaccine.2017.02.039

34. ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations

Author:
Consuelo huerta; Miriam Sturkenboom; Toon Braeye; Lieke van der Aa; Giorgia Danieli; Caitlin Dodd; Talita Duarte-Salles; Hanne- Dorthe Emborg; Marius Gheorghe; Johnny Kahlert; Rosa Gini; Consuelo Huerta-Alvarez; Elisa Martín-Merino; Chris McGee; Simon de Lusignan; Gino Picelli; Giuseppe Roberto; Lara Tramontan; Marco Villa; Daniel Weibel; Lina Titievsky
Source:
Vaccine 2020 v.38 pp. B8
ISSN:
0264-410X
Subject:
computer software; databases; fever; health services; hospitals; injection site; metadata; monitoring; pneumonia; risk; seizures; somnolence; vaccination; vaccine development; vaccines; Europe
Abstract:
... The public-private ADVANCE consortium (Accelerated development of vaccine benefit-risk collaboration in Europe) aimed to assess if electronic healthcare databases can provide fit-for purpose data for collaborative, distributed studies and monitoring of vaccine coverage, benefits and risks of vaccines.To evaluate if European healthcare databases can be used to estimate vaccine coverage, benefit and ...
DOI:
10.1016/j.vaccine.2020.01.100

35. ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling

Author:
Consuelo Huerta; Kaatje Bollaerts; Edouard Ledent; Tom de Smedt; Daniel Weibel; Hanne-Dorthe Emborg; Giorgia Danieli; Talita Duarte-Salles; Consuelo Huerta-Alvarez; Elisa Martín-Merino; Gino Picelli; Lara Tramontan; Miriam Sturkenboom; Vincent Bauchau
Source:
Vaccine 2020 v.38 pp. B65
ISSN:
0264-410X
Subject:
children; databases; fever; injection site; monitoring; multi-criteria decision making; risk; seizures; simulation models; vaccine development; vaccines; Denmark; Italy; Spain; United Kingdom
Abstract:
... The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private collaboration aiming to develop and test a system for rapid benefit-risk (B/R) monitoring of vaccines using electronic health record (eHR) databases in Europe. Proof-of-concept studies were designed to assess the proposed processes and system for generating the required evidence to perform B/R ...
DOI:
10.1016/j.vaccine.2019.09.034

36. ADVANCE system testing: Can coverage of pertussis vaccination be estimated in European countries using electronic healthcare databases: An example

Author:
Consuelo Huerta; Hanne-Dorthe Emborg; Johnny Kahlert; Toon Braeye; Jorgen Bauwens; Kaatje Bollaerts; Giorgia Danieli; Talita Duarte-Salles; Steffen Glismann; Consuelo Huerta-Alvarez; Simon de Lusignan; Elisa Martín-Merino; Chris McGee; Ana Correa; Lara Tramontan; Daniel Weibel; Miriam Sturkenboom
Source:
Vaccine 2020 v.38 pp. B22
ISSN:
0264-410X
Subject:
children; databases; health services; monitoring; vaccination; vaccine development; vaccines; Denmark; Italy; Spain; United Kingdom
Abstract:
... The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private collaboration aiming to develop and test a system for rapid benefit-risk (B/R) monitoring of vaccines, using existing healthcare databases in Europe. The objective of this paper was to assess the feasibility of using electronic healthcare databases to estimate dose-specific acellular pertussis ...
DOI:
10.1016/j.vaccine.2019.07.039

37. ADVANCE system testing: Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination

Author:
Daniel Weibel; Caitlin Dodd; Olivia Mahaux; Francois Haguinet; Tom De Smedt; Talita Duarte-Salles; Gino Picelli; Lara Tramontan; Giorgia Danieli; Ana Correa; Chris McGee; Elisa Martín-Merino; Consuelo Huerta-Alvarez; Klara Berencsi; Hanne-Dorthe Emborg; Kaatje Bollaerts; Vincent Bauchau; Lina Titievsky; Miriam Sturkenboom
Source:
Vaccine 2020 v.38 pp. B38
ISSN:
0264-410X
Subject:
children; databases; fever; health services; hospitals; injection site; monitoring; rapid methods; risk; seizures; somnolence; vaccination; vaccine development; vaccines; Denmark; Italy; Spain; United Kingdom
Abstract:
... The Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE) public-private collaboration, aimed to develop and test a system for rapid benefit-risk monitoring of vaccines using healthcare databases in Europe. The objective of this proof-of-concept (POC) study was to test the feasibility of the ADVANCE system to generate incidence rates (IRs) per 1000 person-years and inci ...
DOI:
10.1016/j.vaccine.2019.06.040

38. ADVANCE system testing: Estimating the incidence of adverse events following pertussis vaccination in healthcare databases with incomplete exposure data

Author:
Consuelo Huerta; Caitlin Dodd; Maria de Ridder; Daniel Weibel; Olivia Mahaux; Francois Haguinet; Tom de Smedt; Simon de Lusignan; Chris McGee; Talita Duarte-Salles; Hanne-Dorthe Emborg; Consuelo Huerta-Alvarez; Elisa Martín-Merino; Gino Picelli; Klara Berencsi; Giorgia Danieli; Miriam Sturkenboom
Source:
Vaccine 2020 v.38 pp. B47
ISSN:
0264-410X
Subject:
children; databases; fever; health services; hospitals; meta-analysis; models; monitoring; rapid methods; risk; seizures; vaccination; vaccine development; vaccines
Abstract:
... The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public–private collaboration aiming to develop and test a system for rapid vaccine benefit-risk monitoring using existing European healthcare databases. Incidence rate (IR) estimates of vaccination-associated adverse events that are needed to model vaccination risks can be calculated from existing healthcare ...
DOI:
10.1016/j.vaccine.2020.03.050

39. ADVANCE: Towards near real-time monitoring of vaccination coverage, benefits and risks using European electronic health record databases

Author:
Kaatje Bollaerts; Tom de Smedt; Chris McGee; Hanne-Dorthe Emborg; Marco Villa; Maria Alexandridou; Talita Duarte-Salles; Rosa Gini; Claudia Bartolini; Simon de Lusignan; Myint Tin Tin Htar; Lina Titievsky; Miriam Sturkenboom; Vincent Bauchau
Source:
Vaccine 2020 v.38 pp. B76
ISSN:
0264-410X
Subject:
Internet; children; cohort studies; databases; disease incidence; monitoring; public-private partnerships; risk; vaccination; vaccine development; vaccines; Denmark; Italy; Spain; United Kingdom
Abstract:
... The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private partnership aiming to develop and test a system for rapid benefit-risk (B/R) monitoring of vaccines using European electronic health record (eHR) databases. This proof-of-concept study aimed to test the feasibility of near real-time (NRT) monitoring of vaccination coverage, benefits and risks ...
DOI:
10.1016/j.vaccine.2019.08.012

40. AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next?

Author:
Leslie A. Reperant; Albert D.M.E. Osterhaus
Source:
Vaccine 2017 v.35 no.35 pp. 4470-4474
ISSN:
0264-410X
Subject:
avian influenza; dengue; emerging diseases; human population; pandemic; pathogens; social change; technology; vector-borne diseases
Abstract:
... Emerging infections have threatened humanity since times immemorial. The dramatic anthropogenic, behavioral and social changes that have affected humanity and the environment in the past century have accelerated the intrusion of novel pathogens into the global human population, sometimes with devastating consequences. The AIDS and influenza pandemics have claimed and will continue to claim million ...
DOI:
10.1016/j.vaccine.2017.04.082
PubMed:
28633891
PubMed Central:
PMC7115365

41. AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period

Author:
Yunda Huang; Kelly E. Seaton; Martin Casapia; Laura Polakowski; Stephen C. De Rosa; Kristen Cohen; Chenchen Yu; Marnie Elizaga; Carmen Paez; Maurine D. Miner; Colleen F. Kelley; Janine Maenza; Michael Keefer; Javier R. Lama; Magdalena Sobieszczyk; Susan Buchbinder; Lindsey R. Baden; Carter Lee; Vineeta Gulati; Faruk Sinangil; David Montefiori; M. Juliana McElrath; Georgia D. Tomaras; Harriet L. Robinson; Paul Goepfert; on behalf of the NIAID-funded HIV Vaccine Trials Network (HVTN) 114 Study Team
Source:
Vaccine 2021 v.39 no.33 pp. 4641-4650
ISSN:
0264-410X
Subject:
DNA; T-lymphocytes; antibodies; durability; epitopes; humoral immunity; immunogenicity; secondary immunization; vaccine development; vaccines
Abstract:
... Eliciting durable humoral immunity with sufficient breadth and magnitude is important for HIV-1 vaccine design. The HVTN 114 vaccine trial evaluated different boost regimens administered after a 7-year rest period in participants previously enrolled in HVTN 205, who received either three MVA/HIV62B (MMM) or two DNA and two MVA/HIV62B (DDMM) injections; both vaccines expressed multiple HIV-1 antige ...
DOI:
10.1016/j.vaccine.2021.06.066

42. AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats

Author:
Akihito Sawada; Katsuhiro Komase; Tetsuo Nakayama
Source:
Vaccine 2011 v.29 no.7 pp. 1481-1490
ISSN:
0264-410X
Subject:
antigens; histopathology; infants; inflammation; models; monkeys; neutralizing antibodies; phenotype; pneumonia; protective effect; rats; vaccines; viruses
Abstract:
... Respiratory syncytial virus (RSV) is the most common cause of respiratory infection in infants, and no vaccine is available. In this report, recombinant AIK-C measles vaccines, expressing the RSV G or F protein of subgroup A (MVAIK/RSV/G or F), were investigated as a RSV vaccine candidate. MVAIK/RSV/G or F had the original ts phenotype and expressed RSV/G or F protein. Cross-reactive neutralizing ...
DOI:
10.1016/j.vaccine.2010.12.028
PubMed:
21185852
PubMed Central:
PMC7127509

43. AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes

Author:
Corey P. Mallett; Edith Beaulieu; Marie-Hélène Joly; Benoît Baras; Xiuhua Lu; Feng Liu; Min Z. Levine; Jacqueline M. Katz; Bruce L. Innis; Sandra L. Giannini
Source:
Vaccine 2015 v.33 no.32 pp. 3784-3787
ISSN:
0264-410X
Subject:
Influenza A virus; adjuvants; animal models; antibodies; antigens; birds; hemagglutinins; mice; vaccines; virion; viruses
Abstract:
... Avian H7 is one of several influenza A virus subtypes that have the potential to cause pandemics. Herein we describe preclinical results following administration of an investigational H7N1 inactivated detergent-split virion vaccine adjuvanted with the AS03 Adjuvant System. The adjuvanted H7N1 vaccine was highly immunogenic compared to the non-adjuvanted H7N1 vaccine in unprimed mice with less than ...
DOI:
10.1016/j.vaccine.2015.06.053

44. AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection

Author:
Yu-Na Lee; Min-Chul Kim; Young-Tae Lee; Hye Suk Hwang; Min-Kyoung Cho; Jong Seok Lee; Eun-Ju Ko; Young-Man Kwon; Sang-Moo Kang
Source:
Vaccine 2014 v.32 no.35 pp. 4578-4585
ISSN:
0264-410X
Subject:
CD4-positive T-lymphocytes; Orthomyxoviridae; Toll-like receptor 4; adjuvants; agonists; cross immunity; dendritic cells; genetic background; immune response; immunoglobulin G; influenza; interferon-gamma; mice; vaccination; vaccines; virus-like particles
Abstract:
... The ectodomain of matrix protein 2 (M2e) of influenza virus is suggested to be a rational target for a universal influenza A vaccine. However, there are some concerns that M2e vaccines might not be highly effective in the general population with diverse genetic backgrounds. Here we examined the immunogenicity and protective efficacy of the baculovirus-derived virus-like particles containing multip ...
DOI:
10.1016/j.vaccine.2014.06.040
PubMed:
24951867
PubMed Central:
PMC4126506

45. AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice

Author:
Richard Stebbings; Gillian Armour; Vivian Pettis; Joanne Goodman
Source:
Vaccine 2022 v.40 no.2 pp. 192-195
ISSN:
0264-410X
Subject:
COVID-19 infection; DNA; blood; brain; intramuscular injection; nerve tissue; particulates; reticuloendothelial system; spinal cord; vaccines
Abstract:
... Biodistribution studies of adenovirus-based vaccines support their clinical development by evaluating their spread and persistence following in vivo administration. AZD1222 (ChAdox1 nCov-19) is a replication-deficient non-human adenovirus-vectored vaccine for coronavirus disease 2019. In this nonclinical study, the biodistribution of AZD1222 was assessed in mice for 29 days following intramuscular ...
DOI:
10.1016/j.vaccine.2021.11.028

46. Abrogation of nontypeable Haemophilus influenzae Protein D function reduces phosphorylcholine decoration, adherence to airway epithelial cells, and fitness in a chinchilla model of otitis media

Author:
Ryan W. Johnson; Glen McGillivary; Philippe Denoël; Jan Poolman; Lauren O. Bakaletz
Source:
Vaccine 2011 v.29 no.6 pp. 1211-1221
ISSN:
0264-410X
Subject:
Haemophilus influenzae; phenotype; biofilm; antibodies; epithelial cells; lipoproteins; models; otitis media; vaccines; mutants; Chinchilla (Chinchillidae)
Abstract:
... The pneumococcal polysaccharide conjugate vaccine which includes a nonacylated protein D carrier from Haemophilus influenzae has been recently licensed for use in many countries. While this vaccine is protective against nontypeable Haemophilus influenzae (NTHI)-induced acute otitis media (OM), the mechanism underlying this protective efficacy is not yet fully understood. Protein D/glycerophosphodi ...
DOI:
10.1016/j.vaccine.2010.12.003

47. Absence of YF-neutralizing antibodies in vulnerable populations of Brazil: A warning for epidemiological surveillance and the potential risks for future outbreaks

Author:
Ana Gabriella Stoffella-Dutra; Jaqueline Silva de Oliveira; Galileu Barbosa Costa; Erna Geessien Kroon; Jônatas Santos Abrahão; Angelle Desiree LaBeaud; Betânia Paiva Drumond; Danilo Bretas de Oliveira; Giliane de Souza Trindade
Source:
Vaccine 2020 v.38 no.42 pp. 6592-6599
ISSN:
0264-410X
Subject:
Yellow fever virus; monitoring; public health; risk; vaccination; vaccines; yellow fever; Brazil
Abstract:
... Yellow Fever (YF) is an acute febrile illness caused by yellow fever virus (YFV), a mosquito-borne flavivirus transmitted to humans and non-human primates. In Brazil, YF is a public health threat and may cause recurrent epidemics, even with the availability of a vaccine. We evaluated the sero-status for YFV in 581 individuals living in a risk area for YF in Brazil. The area presents history of cas ...
DOI:
10.1016/j.vaccine.2020.07.077

48. Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice

Author:
Beatrice Ondondo; Caroline Brennan; Alfredo Nicosia; Steven J. Crome; Tomáš Hanke
Source:
Vaccine 2013 v.31 no.47 pp. 5594-5601
ISSN:
0264-410X
Subject:
HIV infections; Human immunodeficiency virus 1; T-lymphocytes; antigens; antiretroviral agents; blood chemistry; chimerism; clinical trials; food consumption; health services; hematology; intramuscular injection; mice; patients; plasmids; proteome; tissue weight; toxicity; vaccines; viruses; United Kingdom
Abstract:
... The systemic toxicity of three candidate HIV-1 vaccines plasmid pSG2.HIVconsv DNA (D), ChAdV63.HIVconsv (C) and MVA.HIVconsv (M) expressing chimeric immunogen derived from the most conserved regions of the HIV-1 proteome was evaluated in two repeat-dose studies in the male and female BALB/c mice.In study UNO011, mice received three doses of 2×107 plaque-forming units of MVA.HIVconsv vaccine (MMM). ...
DOI:
10.1016/j.vaccine.2013.06.068
PubMed:
23831324
PubMed Central:
PMC3898262

49. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008–2011

Author:
Allison L. Naleway; Brad Crane; Ning Smith; Matthew F. Daley; James Donahue; Julianne Gee; Sharon K. Greene; Theresa Harrington; Lisa A. Jackson; Nicola P. Klein; Hung Fu Tseng; Claudia Vellozzi; Eric S. Weintraub; for the Vaccine Safety Datalink
Source:
Vaccine 2016 v.34 no.1 pp. 167-171
ISSN:
0264-410X
Subject:
adolescents; confidence interval; humans; males; obesity; risk estimate; risk factors; surgery; vaccination; vaccines; young adults
Abstract:
... To investigate concerns about a potential association between quadrivalent human papillomavirus vaccination (HPV4) and venous thromboembolism (VTE), we conducted a self-controlled case series study in adolescents and young adults 9–26 years of age in the Vaccine Safety Datalink.We identified potential VTE cases diagnosed in 2008 through 2011 who had also received at least one HPV4 dose during that ...
DOI:
10.1016/j.vaccine.2015.10.006
PubMed:
26549361
PubMed Central:
PMC4710959

50. Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments

Author:
Angelika Wagner; Joanna Jasinska; Elena Tomosel; Christoph C. Zielinski; Ursula Wiedermann
Source:
Vaccine 2021 v.39 no.51 pp. 7375-7378
ISSN:
0264-410X
Subject:
B-lymphocytes; COVID-19 infection; Severe acute respiratory syndrome coronavirus 2; T-lymphocytes; antibodies; antibody formation; cell proliferation; immunosuppression; organ transplantation; risk; tacrolimus; vaccination; vaccines; viruses
Abstract:
... Patients undergoing immunosuppressive treatments have a higher need for protection against coronavirus disease (COVID19) that follows infection with the SARS-CoV-2 virus but their ability to respond sufficiently to COVID vaccines is uncertain. We retrospectively evaluated SARS-CoV-2 spike subunit 1 (S1)-specific antibody levels after two mRNA doses in 242 patients with underlying chronic inflammat ...
DOI:
10.1016/j.vaccine.2021.10.068